Uniqure Nv (QURE)

$4.69

+0.01

(+0.21%)▲

Market is closed - opens 7 PM, 06 May 2024

Insights on Uniqure Nv

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.40M → 6.68M (in $), with an average increase of 79.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -89.57M → -73.20M (in $), with an average increase of 22.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 50.8% return, outperforming this stock by 128.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.3% return, outperforming this stock by 316.9%

Performance

  • $4.67
    $4.96
    $4.69
    downward going graph

    0.43%

    Downside

    Day's Volatility :5.84%

    Upside

    5.44%

    downward going graph
  • $4.25
    $22.48
    $4.69
    downward going graph

    9.38%

    Downside

    52 Weeks Volatility :81.09%

    Upside

    79.14%

    downward going graph

Returns

PeriodUniqure NvSector (Health Care)Index (Russel 2000)
3 Months
-13.47%
-1.1%
0.0%
6 Months
-23.24%
10.5%
0.0%
1 Year
-78.01%
5.4%
0.5%
3 Years
-84.61%
14.4%
-21.1%

Highlights

Market Capitalization
218.1M
Book Value
$4.34
Earnings Per Share (EPS)
-6.47
PEG Ratio
0.0
Wall Street Target Price
20.85
Profit Margin
0.0%
Operating Margin TTM
-916.34%
Return On Assets TTM
-21.72%
Return On Equity TTM
-90.24%
Revenue TTM
15.8M
Revenue Per Share TTM
0.33
Quarterly Revenue Growth YOY
-93.5%
Gross Profit TTM
-87.4M
EBITDA
-255.1M
Diluted Eps TTM
-6.47
Quarterly Earnings Growth YOY
-0.18
EPS Estimate Current Year
-4.3
EPS Estimate Next Year
-3.86
EPS Estimate Current Quarter
-1.45
EPS Estimate Next Quarter
-1.25

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Uniqure Nv(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
20
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 344.56%

Current $4.69
Target $20.85

Company Financials

FY18Y/Y Change
Revenue
11.3M
↓ 13.91%
Net Income
-83.3M
↑ 3.63%
Net Profit Margin
-738.25%
↓ 124.92%
FY19Y/Y Change
Revenue
7.3M
↓ 35.48%
Net Income
-128.0M
↑ 53.67%
Net Profit Margin
-1.8K%
↓ 1019.9%
FY20Y/Y Change
Revenue
37.5M
↑ 415.23%
Net Income
-125.0M
↓ 2.33%
Net Profit Margin
-333.27%
↑ 1424.88%
FY21Y/Y Change
Revenue
524.0M
↑ 1296.82%
Net Income
329.6M
↓ 363.62%
Net Profit Margin
62.9%
↑ 396.17%
FY22Y/Y Change
Revenue
106.5M
↓ 79.68%
Net Income
-126.8M
↓ 138.47%
Net Profit Margin
-119.07%
↓ 181.97%
FY23Y/Y Change
Revenue
15.8M
↓ 85.12%
Net Income
-308.5M
↑ 143.3%
Net Profit Margin
-1.9K%
↓ 1828.02%
Q3 FY22Q/Q Change
Revenue
1.4M
↑ 191.55%
Net Income
-47.9M
↑ 22.52%
Net Profit Margin
-3.3K%
↑ 4556.6%
Q4 FY22Q/Q Change
Revenue
102.7M
↑ 6990.75%
Net Income
6.8M
↓ 114.22%
Net Profit Margin
6.63%
↑ 3309.39%
Q1 FY23Q/Q Change
Revenue
5.3M
↓ 94.82%
Net Income
-77.2M
↓ 1234.52%
Net Profit Margin
-1.5K%
↓ 1456.9%
Q2 FY23Q/Q Change
Revenue
2.4M
↓ 54.52%
Net Income
-68.5M
↓ 11.33%
Net Profit Margin
-2.8K%
↓ 1376.9%
Q3 FY23Q/Q Change
Revenue
1.4M
↓ 41.91%
Net Income
-89.6M
↑ 30.81%
Net Profit Margin
-6.4K%
↓ 3538.93%
Q4 FY23Q/Q Change
Revenue
6.7M
↑ 375.41%
Net Income
-73.2M
↓ 18.27%
Net Profit Margin
-1.1K%
↑ 5271.68%
FY18Y/Y Change
Total Assets
273.9M
↑ 31.13%
Total Liabilities
94.3M
↓ 20.71%
FY19Y/Y Change
Total Assets
448.6M
↑ 63.79%
Total Liabilities
125.6M
↑ 33.16%
FY20Y/Y Change
Total Assets
340.4M
↓ 24.13%
Total Liabilities
96.5M
↓ 23.16%
FY21Y/Y Change
Total Assets
809.2M
↑ 137.72%
Total Liabilities
213.4M
↑ 121.17%
FY22Y/Y Change
Total Assets
705.0M
↓ 12.88%
Total Liabilities
229.0M
↑ 7.29%
FY23Y/Y Change
Total Assets
831.7M
↑ 17.98%
Total Liabilities
624.0M
↑ 172.55%
Q3 FY22Q/Q Change
Total Assets
638.2M
↓ 8.98%
Total Liabilities
217.1M
↑ 1.09%
Q4 FY22Q/Q Change
Total Assets
705.0M
↑ 10.46%
Total Liabilities
229.0M
↑ 5.48%
Q1 FY23Q/Q Change
Total Assets
631.0M
↓ 10.49%
Total Liabilities
218.2M
↓ 4.68%
Q2 FY23Q/Q Change
Total Assets
942.8M
↑ 49.41%
Total Liabilities
589.4M
↑ 170.1%
Q3 FY23Q/Q Change
Total Assets
871.6M
↓ 7.55%
Total Liabilities
602.8M
↑ 2.26%
Q4 FY23Q/Q Change
Total Assets
831.7M
↓ 4.57%
Total Liabilities
624.0M
↑ 3.53%
FY18Y/Y Change
Operating Cash Flow
-76.0M
↑ 18.31%
Investing Cash Flow
-4.2M
↓ 23.97%
Financing Cash Flow
158.0M
↑ 75.37%
FY19Y/Y Change
Operating Cash Flow
-98.7M
↑ 29.78%
Investing Cash Flow
-6.6M
↑ 56.58%
Financing Cash Flow
248.8M
↑ 57.52%
FY20Y/Y Change
Operating Cash Flow
-134.8M
↑ 36.63%
Investing Cash Flow
-9.5M
↑ 42.68%
Financing Cash Flow
7.4M
↓ 97.01%
FY21Y/Y Change
Operating Cash Flow
288.0M
↓ 313.58%
Investing Cash Flow
-67.4M
↑ 610.53%
Financing Cash Flow
94.9M
↑ 1174.29%
FY22Y/Y Change
Operating Cash Flow
-145.1M
↓ 150.38%
Investing Cash Flow
-182.7M
↑ 171.17%
Financing Cash Flow
1.4M
↓ 98.48%
Q3 FY22Q/Q Change
Operating Cash Flow
-49.0M
↑ 212.48%
Investing Cash Flow
-5.1M
↑ 10.57%
Financing Cash Flow
301.0K
↑ 418.97%
Q4 FY22Q/Q Change
Operating Cash Flow
-54.7M
↑ 11.61%
Investing Cash Flow
-168.2M
↑ 3222.38%
Financing Cash Flow
601.0K
↑ 99.67%
Q1 FY23Q/Q Change
Operating Cash Flow
-78.3M
↑ 43.2%
Investing Cash Flow
3.0M
↓ 101.78%
Financing Cash Flow
131.0K
↓ 78.2%
Q2 FY23Q/Q Change
Operating Cash Flow
-57.0M
↓ 27.21%
Investing Cash Flow
45.8M
↑ 1433.8%
Financing Cash Flow
370.1M
↑ 282447.33%
Q3 FY23Q/Q Change
Operating Cash Flow
38.9M
↓ 168.27%
Investing Cash Flow
-314.1M
↓ 785.28%
Financing Cash Flow
-7.6M
↓ 102.05%

Technicals Summary

Sell

Neutral

Buy

Uniqure Nv is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Uniqure Nv
Uniqure Nv
-8.93%
-23.24%
-78.01%
-84.61%
-92.22%
Moderna, Inc.
Moderna, Inc.
21.5%
73.44%
-8.79%
-23.24%
361.25%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.52%
14.97%
25.57%
98.37%
178.01%
Novo Nordisk A/s
Novo Nordisk A/s
-2.23%
21.74%
50.76%
232.25%
415.39%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.37%
3.97%
15.22%
87.53%
129.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Uniqure Nv
Uniqure Nv
2.64
NA
0.0
-4.3
-0.9
-0.22
NA
4.34
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Uniqure Nv
Uniqure Nv
Buy
$218.1M
-92.22%
2.64
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
361.25%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
178.01%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
415.39%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
129.5%
28.81
36.68%

Institutional Holdings

  • Nantahala Capital Management, LLC

    12.37%

  • Vestal Point Capital LP

    8.20%

  • State Street Corporation

    7.27%

  • BlackRock Inc

    3.84%

  • Morgan Stanley - Brokerage Accounts

    3.68%

  • 683 Capital Management LLC

    3.54%

Company Information

uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Organization
Uniqure Nv
Employees
480
CEO
Mr. Matthew Craig Kapusta
Industry
Health Technology

Discover More

FAQs